PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. The company is headquartered in San Jose, California and currently employs 888 full-time employees. The company went IPO on 2021-09-15. The firm is focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The firm's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
Mr. Larry Wood es el President de Procept Biorobotics Corp, se unió a la empresa desde 2024.
¿Qué tal es el rendimiento del precio de la acción PRCT?
El precio actual de PRCT es de $26.39, ha aumentado un 2.7% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Procept Biorobotics Corp?
Procept Biorobotics Corp pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de Procept Biorobotics Corp?
La capitalización bursátil actual de Procept Biorobotics Corp es $1.4B
¿Es Procept Biorobotics Corp una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 14 analistas han realizado calificaciones de análisis para Procept Biorobotics Corp, incluyendo 5 fuerte compra, 10 compra, 4 mantener, 1 venta, y 5 fuerte venta